Medical News Today: Diagnosing hepatitis C with the hepatitis C antibody test

Learn about the hepatitis C antibody test, which is used to detect when someone has had the hepatitis C virus. What do the results mean?
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

Related Links:

Alimentary Pharmacology&Therapeutics, EarlyView.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionThere might be a global changing figure regarding etiologies of HCC in Latin America. This epidemiological change on the incidence of HCC in the world, although it has been reported, should still be confirmed in prospective studies.
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
ConclusionKi-67 expression associated with progression of CHC disease and prognosis of HCC, while MT was down-regulated in HCC. So both Ki-67 and MT can be used as prognostic and predictive markers in HCC and may be promising molecular candidate for diagnosis and treatment of HCC.
Source: Current Medicine Research and Practice - Category: General Medicine Source Type: research
Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. Following the discovery of HCV 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized care of patients, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for HCV infection and discuss remaining challenges.
Source: Gastroenterology - Category: Gastroenterology Authors: Source Type: research
CONCLUSION: Treating the entire eligible HCV population would lead to significant benefits and savings in managing liver-related diseases and their direct costs, opening opportunities to re-think new settings for the future organisation of liver disease management in the regional health system. PMID: 30321071 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and a leading cause of cancer-related death [1]. HCC usually develops in patients with chronic liver diseases, often related to hepatitis C virus (HCV) infection [2 3]. Although interferon (IFN)-based therapy after HCC treatment reportedly reduces the risk of HCC recurrence [4 5 6], few patients were eligible for IFN therapy after HCC treatment due to aging or advanced liver fibrosis, and its antiviral effect was inversely associated with the rates of adverse effects [7].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Authors: Gigi E, Lagopoulos VI, Bekiari E Abstract Hepatitis C virus (HCV) chronic infection induces liver fibrosis and cirrhosis but is also responsible for a significant portion of hepatocellular carcinoma (HCC) occurrence. Since it was recognized as a causative factor of chronic hepatitis, there have been multiple efforts towards viral eradication, leading to the first-generation HCV treatment that was based on interferon (IFN)-α and its analogs, mainly PEGylated interferon-α (PEG IFNα). Sustained virological response (SVR), defined as the absence of detectable RNA of HCV in blood serum for at ...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Authors: Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, Lubel JS, Kronborg I, Arachchi N, Ryan M, Kemp WW, Knight V, Sundararajan V, Desmond P, Thompson AJ, Bell SJ Abstract OBJECTIVES: To determine the factors associated with survival of patients with hepatocellular carcinoma (HCC) and the effect of HCC surveillance on survival. DESIGN, SETTING AND PARTICIPANTS: Prospective population-based cohort study of patients newly diagnosed with HCC in seven tertiary hospitals in Melbourne, 1 July 2012 - 30 June 2013. MAIN OUTCOME MEASURES: Overall survival (maximum follow-up, 24 months); factors associated w...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Authors: Toniutto P, Bitetto D, Fornasiere E, Fumolo E Abstract Liver transplantation (LT) has become the treatment of choice for a wide range of liver diseases in both adult and pediatric patients. Until recently, the largest proportion of LT in adults, were performed in patients with hepatitis C (HCV) related cirrhosis. The recent availability of safe and effective direct antiviral agents to cure HCV infection in almost all patients whatever the HCV genotype and severity of liver disease, will reduce the need for LT in this category of recipients. Thus, it is presumed that in the next 1 to 2 decades HCV related l...
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
Abstract Introduction Hepatitis C virus (HCV) infection leads to important morbidity and mortality through liver disease and extra-hepatic manifestations. Recent evidence suggests the role of HCV in developing chronic kidney disease (CKD); also, HCV adversely impacts on cardiovascular (CV) disease both in the general population and in patients with CKD. Areas covered All-oral, interferon-free direct-acting antiviral agents are currently available; anti-HCV regimens based on direct-acting antiviral agents (DAAs) are provided with high efficacy and safety and short treatment duration. However, some difficult-to-trea...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research
More News: Health | Hepatitis | Hepatitis C | Learning | Liver | Liver Disease | Universities & Medical Training | Urology & Nephrology